This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing Centessa's Phase 2a & Phase 1 Data for ORX750 and ORX142 (OX₂R Agonists) in NT1, NT2 and Idiopathic Hypersomnia

Ticker(s): CNTA

Who's the expert?

Institution: Stanford

  • Clinical Associate Professor, Neurology & Neurological Sciences  & Clinical Associate Professor, Psychiatry and Behavioral Sciences - Sleep Medicine at Stanford.
  • Manages 40 patients with narcolepsy and has prescribed SUNOSI.
  • Research interests involve biomarkers of disease progression in REM sleep behavior disorder, and mechanisms and treatment of Postural Tachycardia Syndrome and Post-Acute COVID Syndrome; special interest in Autonomic Disorders, Sleep Disorders, and the interaction between these conditions.

Interview Goal
To gain a deeper understanding of Centessa's ORX750 and ORX142 as potential treatments for NT1, NT2 and idiopathic hypersomnia

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.